Next-generation spirobenzazepines: Identification of RWJ-676070 as a balanced vasopressin V1a/V2 receptor antagonist for human clinical studies
作者:Min Amy Xiang、Philip J. Rybczynski、Mona Patel、Robert H. Chen、David F. McComsey、Han-Cheng Zhang、Joseph W. Gunnet、Richard Look、Yuanping Wang、Lisa K. Minor、H. Marlon Zhong、Frank J. Villani、Keith T. Demarest、Bruce P. Damiano、Bruce E. Maryanoff
DOI:10.1016/j.bmcl.2007.09.059
日期:2007.12
We have continued to explore spirobenzazepines as vasopressin receptor antagonists to follow up on RWJ-339489 (2), which had advanced into preclinical development. Further structural modi. cations were pursued to find a suitable backup compound for human clinical studies. Thus, we identified carboxylic acid derivative 3 (RWJ-676070; JNJ-17158063) as a potent, balanced vasopressin V-1a/V-2 receptor antagonist with favorable properties for clinical development. Compound 3 is currently undergoing human clinical investigation. (c) 2007 Elsevier Ltd. All rights reserved.